Zacks Investment Research Downgrades H. Lundbeck A/S- (HLUYY) to Hold

Zacks Investment Research downgraded shares of H. Lundbeck A/S- (OTCMKTS:HLUYY) from a buy rating to a hold rating in a research report report published on Thursday morning.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

H. Lundbeck A/S- (HLUYY) opened at $47.66 on Thursday. H. Lundbeck A/S- has a 52-week low of $38.21 and a 52-week high of $66.67. The stock has a market capitalization of $9,486.63, a P/E ratio of 22.06, a PEG ratio of 0.99 and a beta of 0.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.21 and a quick ratio of 0.93.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Downgrades H. Lundbeck A/S- (HLUYY) to Hold” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply